CBD: A Broad Spectrum Pharmaceutical

Cannabidiol, commonly known as CBD, is gaining grounds around the world for its therapeutic benefits. Researchers have made successful discoveries about its efficacious nature against conditions like cancer, epilepsy, and Alzheimer’s. These developments showcase the potential of CBD as a broad spectrum pharmaceutical to treat a wide range of medical ailments.

CBD is the non-psychoactive component of medical cannabis. It works well with the endocannabinoid system of the human body. The receptors of the endocannabinoid system bind with the administered CBD. The binding enhances the functioning of the body’s organ systems like the immune system, skin, and gastrointestinal tract, unlike any other medication. These benefits of CBD can push the compound to become a broad-spectrum therapeutic drug that can treat many ailments.

Many biopharmaceutical companies are actively working to introduce breakthrough products. Medical conditions like cancer, epilepsy, seizures, multiple sclerosis, acute pain, and Alzheimer’s still lack effective treatments. Kalytera Therapeutics, a biotechnology company, is in the process of developing a CBD product to treat spinal-cord injuries. It is a targeted delivery product that combines cannabinoid with a painkiller.

Similarly, Tetra Bio-Pharma, another biopharmaceutical, is involved in Phase 2 clinical trials for its encapsulated CBD oil product. This product can treat chronic pain. The company is obtaining the safety and efficacy data for the product to understand its potential against opiates.

The existing medications for these diseases can have catastrophic side effects. The healthcare sector is facing a void that needs to be filled with innovative products to improve life expectancy.

In addition to this, the infusion of cannabidiol in cosmetics and skincare products to treat skin problems has become a fad. The result-oriented benefits of the compound are also helping it penetrate into multiple industries like food and beverage and lifestyle.

From the investor’s point of view, many analysts suggest the cannabidiol industry offers promising opportunities for growth. The industry is currently at its nascent stage and thus has immense potential in terms of intellectual property rights. In other words, biotech companies can create patent-worthy drugs, therapies, and delivery techniques.

Besides this, the markets for cancer and pain have enormous commercial opportunities, representing $121 billion and $83 billion in 2017.


Read more: ‘CBD: The Biotech Boom Investors Haven’t Woken Up To Yet’

Leave a Reply

Your email address will not be published.